Rapid Therapeutic Announces Its Plans to Utilize Its Proprietary Technology to Address Broad Applications for Delivery of Medications via the Pulmonary System to Focus on Addressable Markets of Over $7 Billion

Stock Information for Rapid Therapeutic Science Laboratories Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Rapid Therapeutic Science Laboratories Inc

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Rapid Therapeutic Science Laboratories, Inc.
White House Office of Management and Budget review on Cannabis-Derived Products confirms Rapid Therapeutic Science Laboratories' Long-Term Strategy
Rapid Therapeutic Science Laboratories Updates Patents
Rapid Therapeutic Science Laboratories File S1 and completes Mid-Year Strategy Review
Rapid Therapeutic Science Laboratories to Attend the Respiratory Drug Delivery (RDD) 2022 Conference
Rapid Therapeutic Science Laboratories to Present at the Benzinga Global Small Cap Conference
Rapid Therapeutic Science Laboratories to Present at the Q4 Investor Summit Conference
Rapid Therapeutic Science Laboratories Secures Upgraded Laboratory and Manufacturing Facility

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.